Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study

The role of metformin in prostate cancer chemoprevention remains unclear. REDUCE, which followed biopsy-negative men with protocol-dictated PSA-independent biopsies at 2- and 4-years, provides an opportunity to evaluate the link between metformin use and prostate cancer diagnosis with minimal confou...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Prev Res (Phila)
Autors principals: Feng, Tom, Sun, Xizi, Howard, Lauren E., Vidal, Adriana C., Gaines, Alexis R., Moreira, Daniel M., Castro-Santamaria, Ramiro, Andriole, Gerald L., Freedland, Stephen J.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4651624/
https://ncbi.nlm.nih.gov/pubmed/26353947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-15-0141
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars